Vaccine development for tuberculosis: Current progress

Drugs

Volumn 73, Issue 10, 2013, Pages 1015-1024

  Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AERAS 402; BCG VACCINE; CXCL11 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; H 1; H 4; H 56; HYBRID 4; HYBRID PROTEIN; ID 93; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 2; ISONIAZID; LISTERIOLYSIN; M 72; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLACEBO; RECOMBINANT VACCINE; RIFAMPICIN; RIFAPENTINE; RUTI; SETAZINDOL; TOLL LIKE RECEPTOR AGONIST; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VMP 1002;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM MUTANT; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION SITE REACTION; LOW DRUG DOSE; MYCOBACTERIUM; MYCOBACTERIUM INDICUS PRANII; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS; VACCINATION REACTION;

ANIMALS; CHILD; DRUG DESIGN; HUMANS; INFANT; MODELS, ANIMAL; MYCOBACTERIUM BOVIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

ANIMALIA; MYCOBACTERIUM BOVIS BCG;

EID: 84879902560     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0081-8     Document Type: Article

References (72)

1. Smith KC, Orme IM, Starke J. The BCG Vaccine. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed. London: WB Saunders; 2012.
2. Andersen P, Doherty TM. The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3:656-62.
3. Orme IM. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol. 2011;6:161-77.
4. Orme IM. New vaccines against tuberculosis: the status of current research. Infect Dis Clin North Am. 1999;13:169-85.
5. Andersen P. TB vaccines: progress and problems. Trends Immunol. 2001;22:160-8.
6. Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nat Med. 2000;6:955-60.
7. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 1 Feb 2013 (Epub ahead of print).
8. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci. 2013;366:2782-9.
9. Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010;181:1407-17.
10. Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004;172:7618-28.
11. Brandt L, Skeiky YA, Alderson MR, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun. 2004;72:6622-32.
12. Spertini F, Audran R, Lurati F, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb). 2012;93:179-88.
13. Day CL, Tameris M, Mansoor N, et al. Induction and Regulation of T Cell Immunity by the Novel TB Vaccine M72/AS01 in South African Adults. Am J Respir Crit Care Med. 10 Jan 2013 (Epub ahead of print).
14. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17:189-94.
15. Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest. 2012;122:303-14.
16. Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug resistant Mycobacterium tuberculosis. Sci Transl Med. 2010;2(53):53ra74.
17. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol. 2012;188:2189-97.
18. Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One. 2012;7:e39909.
19. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol. 2003;171:1602-9.
20. McShane H. Developing an improved vaccine against tuberculosis. Expert Rev Vaccines. 2004;3:299-306.
21. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun. 2001;69:681-6.
22. McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 2005;7:962-7.
23. Williams A, Goonetilleke NP, McShane H, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun. 2005;73:3814-6.
24. White AD, Sibley L, Dennis MJ, et al. An evaluation of the safety and immunogenicity of a candidate TB vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol. 2013;20(5):663-72.
25. Meyer J, Harris SA, Satti I, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine. 2013;31:1026-33.
26. Kato-Maeda M, Shanley CA, Ackart D, et al. Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vacc Immunol. 2012;19:1-10.
27. Ordway DJ, Shang S, Henao-Tamayo M, et al. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol. 2011;18:1527-35.
28. Shang S, Harton M, Tamayo MH, et al. Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis (Edinb). 2011;91:378-85.
29. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest. 2005;115:2472-9.
30. Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013;31:1340-8.
31. Nambiar JK, Pinto R, Aguilo JI, et al. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol. 2012;42:385-92.
32. Verreck FA, Vervenne RA, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One. 2009;4:e5264.
33. Orme IM. The Achilles heel of BCG. Tuberculosis (Edinb). 2010;90:329-32.
34. Hinchey J, Jeon BY, Alley H, et al. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS One. 2011;6:e15857.
35. Sambandamurthy VK, Derrick SC, Hsu T, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine. 2006;24:6309-20.
36. Sambandamurthy VK, Derrick SC, Jalapathy KV, et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun. 2005;73:1196-203.
37. Sambandamurthy VK, Jacobs WR Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 2005;7:955-61.
38. Sampson SL, Dascher CC, Sambandamurthy VK, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun. 2004;72:3031-7.
39. Zimmerman DM, Waters WR, Lyashchenko KP, et al. Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats infected with feline immunodeficiency virus. Clin Vaccine Immunol. 2009;16:427-9.
40. Hinchey J, Lee S, Jeon BY, et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest. 2007;117:2279-88.
41. Sweeney KA, Dao DN, Goldberg MF, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med. 2011;17:1261-8.
42. Turner J, Rhoades ER, Keen M, Belisle JT, Frank AA, Orme IM. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun. 2000;68:1706-9.
43. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006;86:273-89.
44. Gil O, Vilaplana C, Guirado E, et al. Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol. 2008;15:1742-4.
45. Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010;28:1106-16.
46. Coler RN, Bertholet S, Pine SO, et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis. 2013;207(8):1242-52.
47. Turner OC, Keefe RG, Sugawara I, Yamada H, Orme IM. SWR mice are highly susceptible to pulmonary infection with Mycobacterium tuberculosis. Infect Immun. 2003;71:5266-72.
48. Faujdar J, Gupta P, Natrajan M, et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J Med Res. 2012;134:696-703.
49. Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 2012;7:e39215.
50. Ordway DJ, Shanley CA, Caraway ML, et al. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2010;54:1820-33.
51. Rawat KD, Chahar M, Reddy PV, et al. Expression of CXCL10 (IP-10) and CXCL11 (I-TAC) chemokines during Mycobacterium tuberculosis infection and immunoprophylaxis with Mycobacterium indicus pranii (Mw) in guinea pig. Infect Genet Evol. 2012;13:11-7.
52. Gupta A, Ahmad FJ, Ahmad F, et al. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine. 2012;30:6198-209.
53. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2012;24:675-85.
54. Orme IM. The mouse as a useful model of tuberculosis. Tuberculosis (Edinb). 2003;83:112-5.
55. Rhoades ER, Frank AA, Orme IM. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis. 1997;78:57-66.
56. Turner OC, Basaraba RJ, Frank AA, Orme IM. Granuloma formation in mouse and guinea pig models of experimental tuberculosis. In: Boros DL, editor. Granulomatous infections and inflammation: cellular and molecular mechanisms. Washington DC: ASM Press; 2003. p. 65-84.
57. Driver ER, Ryan GJ, Hoff DR, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56:3181-95.
58. Kramnik I. Genetic dissection of host resistance to Mycobacterium tuberculosis: the sst1 locus and the Ipr1 gene. Curr Top Microbiol Immunol. 2008;321:123-48.
59. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol. 2009;174:2190-201.
60. Basaraba RJ, Orme IM. Pulmonary tuberculosis in the guinea pig. In: Leong FY, Dartois V, Dick T, editors. A color Atlas of comparative pathology of pulmonary tuberculosis. Baton Rouge: CRC Press; 2010.
61. Basaraba RJ. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb). 2008;88(Suppl 1):S35-47.
62. Ordway DJ, Orme IM. Animal models of mycobacteria infection. Curr Protoc Immunol. Chapter 19: Unit 19 5.
63. Hoff DR, Ryan GJ, Driver ER, et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One. 2011;6:e17550.
64. Ryan GJ, Hoff DR, Driver ER, et al. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS One. 2010;5:e11108.
65. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845-55.
66. Orme M. The latent tuberculosis bacillus (I'll let you know if I ever meet one). Int J Tuberc Lung Dis. 2001;5:589-93.
67. Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun. 2009;77:4631-42.
68. Sharpe SA, McShane H, Dennis MJ, et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol. 2010;17:1170-82.
69. Williams A, Hall Y, Orme IM. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb). 2009;89:389-97.
70. Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci. 2011;32:601-6.
71. Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet. 2010;42:498-503.
72. McShane H, Jacobs WR, Fine PE, et al. BCG: myths, realities, and the need for alternative vaccine strategies. Tuberculosis (Edinb). 2012;92:283-8.